top of page

Allogenica’s bioproduction process consists in:

Transferring therapeutic transgene to these immature cells (called pre-T cells)

2

Transferring therapeutic transgene to these immature cells
Harvesting stem cell from healthy donors

Harvesting stem cell from healthy donors

1

Our commitment

Inna MENKOVA

We are committed to making T-cell therapies universally accessible by delivering treatments that are safer, more readily available to patients, and up to ten times less expensive to manufacture.

While cancer remains our primary focus, we also aim to address rare diseases and autoimmune disorders.

Inna MENKOVA, PhD

CEO and Co-founder of ALLOGENICA

Cell therapy

WHY Allogenica

Our unique approach

4

After production, engineered pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them

engineered pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them
Differentiate and expand the engineered pre-T cells at large scale in a bioreactor

Differentiate and expand the engineered pre-T cells at large scale in a bioreactor

3

Allogenica's unique expertise enables the differentiation of stem cells into immature precursor T cells. Allogenica's innovative vector allows these cells to be modified to produce a new generation of allogeneic T-cell therapies.

Allogenica’s most advanced drug candidate is expected to enter clinical trials in 2026.

Approach241205.png

Allogenica’s solution

Allogenica has developed unique worldwide expertise:

Latest news